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Am J Med Genet Part A 9999:1–7.PTEN hamartoma tumor syndromes (PHTS) are a spectrum of
hamartomatous overgrowth syndromes associated with germ-
line mutations in the tumor suppressor PTEN gene located on
10q23.3. It iswidely accepted that twoof thesedisorders,Cowden
syndrome and Bannayan–Riley–Ruvalcaba syndrome, are allelic
conditions.BecausePTENmutations arenot identifiable in every
case of the PHTS phenotype, the inability to detect a mutation
within thePTEN genedoesnot invalidate the clinical diagnosis of
Cowden syndrome, or Bannayan–Riley–Ruvalcaba syndrome, in
patients who meet diagnostic criteria for these disorders. PTEN
mutations are associated with an increased risk for developing
breast, thyroid, endometrial, and sometimes renal cancers.Thus,
cancer surveillance is the cornerstone of PHTS patient manage-
ment. Although a consensus cancer surveillance protocol has not
been formally instituted, all PTEN mutation carriers should
adopt the cancer surveillance strategies proposed for patients
with Cowden syndrome. In addition, because gastrointestinal
and vascular complications can be more severe in Bannayan–
Riley–Ruvalcaba syndrome than in Cowden syndrome, patients
with Bannayan–Riley–Ruvalcaba syndrome should be moni-
tored from this point of view too. In this study, we report on
two cases with Bannayan–Riley–Ruvalcaba phenotype that
showed two different PTENmutations.We also propose practice
recommendations for management of PHTS patients.
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PTEN hamartoma tumor syndromes (PHTS) are a collection of
rare clinical syndromes inherited in an autosomal dominant man-
ner and associated with germ-line mutations of the tumor sup-
pressor gene PTEN (OMIM 601728) [Eng, 2000]. The PTEN
(phosphate, tensin homologue, deleted on chromosome 10)
gene encodes a dual-specificity phosphatase that antagonizes the2013 Wiley Periodicals, Inc.phosphoinositol-3-kinase (PI3K)/Akt pathway, leading to G1 cell-
cycle arrest and/or apoptosis and also inhibits cell spreading via the
focal adhesion kinase pathway [Sansal and Sellers, 2004]. PHTS
encompass Cowden syndrome (CS; OMIM 158350), Bannayan–
Riley–Ruvalcaba syndrome (BRRS; OMIM 153480), and Proteus-
like syndrome. Of these three entities, CS, occurring in adulthood,
and BRRS, a pediatric syndrome, have many overlapping features
(macrocephaly, hamartomas, and thyroid abnormalities). Given
the clinical similarities between these disorders, the hypothesis of a
common genetic pathogenesis has been validated by detection of an
identical PTENmutation in different members of the same family
[Marsh et al., 1997]. Therefore, the difference between the two
conditions is the age of presentation. Both are considered allelic. CS
is an autosomal dominant disorder characterized by multiple
hamartomatous lesions (trichillemmomas, oral papillomas, intes-
tinal polyps), and by an increased risk of breast, thyroid, and
endometriumcancers [Liawet al., 1997].Clinical diagnostic criteria
for CS are shown in Table I. Both simplex and familial cases of CS
have been identified. However, most CS cases are isolated [Marsh1
TABLE I. Operational Criteria for Cowden Syndrome without Family
History of Known PTEN Mutation Adapted from Tan et al. [2011]
Pathognomonic criteria
Adult Lhermitte–Duclos disease (cerebellar tumors)
Mucocutaneous lesionsa
Facial trichilemmomas, any numbera (at least two biopsy-proven
trichilemmomasb)
Acral keratoses
Papillomatous papules
Mucosal lesions
Autism spectrum disorder and macrocephalyb
Major criteria
Breast cancer
Epithelial thyroid cancer (follicular and papillary, never medullary)
Macrocephaly (megalocephaly) (i.e., 97th percentile and above)
Endometrial cancer
Mucocutaneous lesionsb
One biopsy-proven trichilemmoma
Multiple palmoplantar keratoses
Multifocal cutaneous facial papules
Macular pigmentation of glans penis
Multiple gastrointestinal hamartomas or ganglioneuromasb
Minor Criteria
Other thyroid lesions (e.g., adenoma, multinodular goiter)
Intellectual disability (i.e., IQ of 75 and below)
Gastrointestinal hamartomasa (single gastrointestinal hamartoma
or ganglioneuromab)
Fibrocystic disease of the breast
Lipomas
Fibromas
Genitourinary tumors (especially renal cell carcinoma)
Genitourinary malformationsa
Uterine fibroids
Autism spectrum disorderb
aPresent in this section as defined by ICC criteria only.
bPresent in this section as defined by NCCN 2010 criteria only.
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the majority of CS cases [Liaw et al., 1997; Marsh et al., 1998]. The
molecular basis of CS in the remaining cases has yet to be deter-
mined. BRRS is a rare congenital syndrome characterized by
macrocephaly,multiple hemangiomas, and lipomas (subcutaneous
and/or visceral), gastrointestinal hamartomatous polyps, neuro-
logicmanifestations (autismor cognitive andmotordevelopmental
delay), and hyperpigmented macules on the skin of the shaft
and glans penis [Gorlin et al., 1992]. Common features include
hypotonia associated with a lipid storage myopathy [DiLiberti
et al., 1984] and thyroid abnormalities such as Hashimoto’s thy-
roiditis [Gorlin et al., 1992]. Clinical findings of BRRS are shown in
Table II. Most BRRS cases have a family history, and are inherited
in an autosomal dominant manner [Zonana et al., 1975].
However, there are sporadic cases that do not belong to classic
BRRS pedigrees [Carethers et al., 1998]. Germ-line PTEN muta-
tions are reported in over half of the patients with BRRS. In contrast
with CS, there are no agreed international criteria for the diagnosisof BRRS. However, after the discovery of the PTEN gene, it became
apparent that PTEN mutation testing might facilitate early
diagnosis in childhood [Marsh et al., 1997; Mester et al., 2011].
Recently a prospective multicenter study defined clinical criteria
useful to decide which pediatric (<18 years) patients to test for
PTEN (Table III) [Tan et al., 2011]. However, BRRS is not always
associated with germ-line mutations in the PTEN gene [Carethers
et al., 1998]. Therefore, other molecular mechanisms could
have occurred to cause the BRRS cases without germ-line PTEN
mutations.
MATERIALS AND METHODS
Clinical Report
Patient 1 was a 6 1/2-year-old female, third child of noncon-
sanguineous healthy parents. After an uncomplicated pregnan-
cy, she was born at 38 weeks gestation by cesarean due to
polyhydramnios. Her birth weight was 3,270 g (50th–75th cen-
tile), length 51 cm (75th–90th centile), and OFC 36 cm (>97th
centile). At 1-month of life, generalized hypotonia was noted, for
which physiochynesitherapy was started. Because of develop-
ment (motor, cognitive, and language) delay, some diagnostic
investigations were performed. Neurological examination,
electroencephalogram, and cranial Computed Tomography
scan did not reveal any brain abnormalities; visual evoked
potential (VEP) and auditory brain stem responses to complex
sounds (cABRs) were normal too. At 4 years and 10 months of
age, she developed a right cervical swelling. Ultrasound study
showed a hyperechogenic swelling (4.5 cm 3.5 cm) in right
supraclavicular region. Thorough investigation with Positron
emission tomography (PET) failed to reveal any tumor illness
with high metabolic activity in right lateral cervical and thoracic
regions. Therefore, the patient underwent excision of right
cervical-axillary lesion. Findings from histopathologic exami-
nation of this lesion were interpreted as a lipoma. As a result of
these clinical and anamnestic features the patient was referred
to genetic counseling. At first observation, the patient was 6
1/2-years old. Prominent physical findings included macroce-
phaly (Fig. 1a,b), with OFC of 58 cm (>95th centile), and
overweight, with a weight of 33.5 kg (>95th centile). Her height
was normal. A severe scoliosis was noted, and bilateral pes planus
was present too. Examination of patient’s parents and siblings
didn’t reveal physical abnormalities. Because of macrocephaly,
psychomotor and cognitive delay, and lipomatosis we decided to
study PTEN gene.
Patient 2 was a female of 24 months of age. She was first-born
to nonconsanguineous healthy parents. She was born at 41.3
weeks gestation from uneventful pregnancy and spontaneous
delivery. Her birth weight was 3,730 g (75th–90th centile), length
51 cm (50th–75th centile), and OFC 36.5 cm (>97th centile). By
8 weeks of age, her OFC at 42 cm was >97th centile. Early
cognitive and language milestones were reached normally, but
she started to walk at 22 months of age. During this period, she
was noticed to have multiple thoraco-abdominal swelling
(Fig. 2a,b), which revealed lipomas after excision. Thus, she
was referred to our genetic evaluation at 24 months of age: she
weighed 12.5 kg (25th–50th centile), 87 cm tall (50th centile),
TABLE II. A Broad Spectrum of Clinical Findings can be Associated with Variable Expressivity among BRRS Patients
Features present at birth Overgrowth of prenatal and/or postnatal onset: OFC and/or weight and length 98th centile
Neonatal hypotonia
Facial dysmorfic features Frontal bossing, hypertelorism, downward slanting palpebral fissures, depressed nasal bridge, strabismus,
epicanthus inversus, small beaked nose, long philtrum, thin upper lip, broad mouth, and relative micrognathia
[Hendriks et al., 2003]
Ophthalmologic abnormalities Pseudopapilloedema
Prominent Schwalbe lines
Prominent corneal nerves [Riley and Smith, 1960]
Hamartomatous lesions Hemangiomas and lipomas (subcutaneous and/or visceral)
Gastrointestinal polyps
Mucocutaneous abnormalities Hyper-pigmented penile macules in males
Cafe` au lait spots
Acanthosis nigricans-like
Oral, facial and acral warts or verrucous papules Cutis marmorata and telangiectases [Erkek et al., 2005]
Cardiovascular abnormalities Arteriovenous malformations, shunts, and fistula
Local overgrowth of small vessels
Aneurysms of aortic root ad ascending aorta [Tan et al., 2007]
Unstable angina and atrial septal defect [Halal and Silver, 1989]
Thyroid involvement Hashimoto’s thyroiditis
Multinodular goiter, adenoma, cancer
Neurological abnormalities Autism
Cognitive, speech, and motor development delay
Incoordination
Mild mental deficiency
Seizures (25% of patients) [Gorlin et al., 1992]
Rare peripheral neuropathy [Erkek et al., 2005]
Skeletal system abnormalities High palate, scaphocephaly, scoliosis, joint hyperextensibility, pectus excavatum, pes planus
[Boccone et al., 2006]
Punctate cystic changes in acral tubular bones, enostosis of talus, broad thumbs and great toes
[Erkek et al., 2005]
PICCIONE ET AL. 3and her OFC was 51 cm (>97th centile). Physical examination
revealed extreme macrocephaly, epicanthus, and three cafe´-au-
lait macules on her trunk, only one measuring greater than
2.5 cm in diameter. A tonsil papilloma was observed too
(Fig. 2c). Her parents had not macrocephaly. As result of the
phenotype we performed PTEN molecular analysis.TABLE III. Pediatric Clinical Criteria for PTEN Testing

Adapted from
Tan et al. [2011]
Clinical features
Macrocephaly (2 SD)
At least one of the following four additional criteria should be present:
Autism or developmental delay
Dermatological features, including lipomas, trichillemmomas, oral
papillomas, penile freckling
Vascular features, such as arteriovenous malformations or
hemangiomas
Gastrointestinal polyps
 In addition, pediatric-onset thyroid cancer and germ cell tumors (testicular cancer
and dysgerminoma) are recognized associations of Cowden Syndrome and should provoke
consideration of PTEN testing.RESULTS
PTEN Molecular Analysis
Molecular genetic analysis was performed on genomic DNA
extracted from peripheral blood leukocytes. Real-time quantitative
multiplexPCRanalysis and a sequence analysis ofPTEN exons (1, 2,
3, 4, 5, 6, 7, 8, and 9) and promoter region were performed [Zhou
et al., 2003]. In patient 1 a de novo heterozygousmutation in exon 8
of PTEN (c.959T>A) was identified at codon 320 leading to
premature termination of the protein (p.Leu320X). Based on
literature review, germ-line mutation p.Leu320X was already
reported in both variants c.959T>A and c.959T>G in patients
with Cowden syndrome [Nelen et al., 1999; Eng, 2003]. In patient 2
PTEN mutational analysis showed a de novo heterozygous muta-
tion in exon 7 (c.703G>T) resulting in a premature stop at codon
235 (p.Glu235X). To our knowledge, this mutation has never been
reported in BRRS patients.DISCUSSION
In this paper we report our experience following two patients with
BRRS phenotype and germ-line PTEN mutations. Both patients
came to our attention for clinical features suggestive of BRRS
such as macrocephaly, developmental delay, and subcutaneous
FIG. 1. Patient 1 at age six and half-years. There are no
strikingly dysmorphic features; however, macrocephaly was
clearly visible both in front (a) and side (b) view.
FIG. 2. Patient 2 was first evaluated at age of 24 months for
multiple thoraco-abdominal swelling (a,b). Physical examination
revealed mild tonsillar hypertrophy and a papilloma on the right
side (c).
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the most consistent finding in BRRS in several reviews [Moretti-
Ferreira et al., 1989; Gorlin et al., 1992]. It is noteworthy that
macrocephaly is usually present from birth and persists into
adulthood [DiLiberti, 1998]. Motor delay or learning difficulties
occur in most children diagnosed with BRRS [Gorlin et al., 1992].
However, most specific finding in the PHTS is presence of hamar-
tomatous lesions. In both our patients, the diagnosis of BRRS has
not been suspected until lipomas were identified. In Patient 1 we
found a de novo heterozygous mutation in exon 8 of PTEN
(c.959T>A) previously described in CS, confirming that these
diseases are allelic, and suggesting that the phenotype may not
be predictable on the basis of molecular analysis. It is therefore
expected that no clear phenotype–genotype correlation will be
made, and that patients with identical mutations may show differ-
ent phenotype. In Patient 2 a de novo heterozygous mutation in
exon 7 of PTEN has been identified at codon 703 (c.703G>T). This
specificmutation has not beenpreviously described in patientswith
BRRS, but it is likely to be pathogenic because it inactivates PTEN
protein expression. ThePTEN is a tumor suppressor genewith nineexons, which maps to human chromosome 10q23.31. It is also
known as MMAC1 (Mutated in Multiple Advanced Cancers 1)
[Steck et al., 1997] and TEP1 (TGF- regulated and Epithelial cell-
enriched Phosphatase 1) [Li and Sun, 1997], and it encodes a 403
amino acid protein, which is a dual-specificity phosphatase since it
can recognize both protein and phospholipid substrates [Li and
Sun, 1997; Myers et al., 1998]. Most PTEN protein functions are to
cause G1 cell-cycle arrest and/or apoptosis, and to inhibit cell
migration [Sansal and Sellers, 2004]. Overall, decreased PTEN
protein expression correlates with unregulated cellular prolifera-
tion. Somatic PTEN deletions and/or mutations occur with a wide
distribution of frequencies in sporadic primary tumors, such as
endometrial carcinomas, glioblastomamultiform, prostate cancer,
breast cancer, and melanomas [De Vivo et al., 2000]. Germ-line
PTENmutations have been identified in patients suffering fromCS
[Marsh et al., 1998], BRRS [Longy et al., 1998], and Proteus-like
syndrome [Zhou et al., 2001]. However, two additional disease
phenotypes may also be associated with germ-line mutation or
deletion of the PTEN gene. Germ-line PTENmutations have been
found in 10–20% of patients with autism spectrum disorder (ASD)
TABLE IV. Follow-Up Protocol for PHTS. Modified from Eng [2000]
and Tan et al. [2012]
General surveillance
Annual physical examinationa
Annual dermatologic examinationa
Formal neurologic and psychological testing (<18 years)
Annual surveillance with fecal occult blood test (FOBT)b
Specific surveillance for thyroid cancer
Annual thyroid ultrasound examinationa
Specific surveillance for breast cancer
Women
Monthly breast self-examination beginning at age 18 years
Annual clinical breast examination beginning at age 25
yearsc
Annual mammography and breast MRI beginning at age 30
yearsc
Men should perform monthly breast self-examination
Specific surveillance for endometrial cancer
Premenopausal women. Annual endometrial sampling
beginning at age 30 yearsc
Postmenopausal women. Annual trans-vaginal ultrasound
examination with biopsy of suspicious areas
Specific surveillance for other specific cancer
Biannual colonoscopy beginning at age 40 yearsc
Annual urinalysis and biannual renal ultrasound/MRI
beginning at age 40 yearsc
aSurveillance may be recommend in all patients upon the diagnosis of PHTS, regardless of their
age.
bFOBT should be considered for the early detection of intestinal hamartomas, which are not
believed to increase the risk for colorectal cancer, but may be associated with complications
(intussusception, rectal bleeding).
cSurveillance may begin 5 or 10 years before the earliest onset of a specific cancer in the family,
but not later than the recommended age cutoff point.
FIG. 3. Patient 2: The tonsil papilloma became larger and
rougher after 6 months.
PICCIONE ET AL. 5and extrememacrocephaly, evenwithout other features of BRRS or
CS [Butler et al., 2005]. A germ-linemutation (H61D)has also been
reported in a patientwith features of VATERassociation (vertebral,
anal, radial, and renal malformations in patients with esophageal
atresia or tracheoesophageal fistula), hydrocephalus, and macro-
cephaly [Reardon et al., 2001]. To date, over 100 germ-line PTEN
mutations have been found in CS e BRRS [Eng, 2003]. These
mutations are distributed along the length of the gene, with the
exception of exon 9 (no mutation reported) [Bonneau and
Longy, 2000]. Most of the mutations have been found in exon 5,
7, and 8, especially in exon 5, which encodes the N-terminal
phosphatase catalytic domain [Marsh et al., 1998].
Although the clinicalmanifestations ofPHTSdiffer significantly,
all four syndromes are characterizedby aberrant tissue growth likely
related to tumor suppressor role of PTEN gene. Genotype–pheno-
type analyses revealed an association between the presence of PTEN
mutation in BRRS and the development of benign tumor of various
tissues and organs (lipomas, hemangiomas, thyroid adenoma,
gastrointestinal hamartomatous polyps) [Hendriks et al., 2003].
However, the most serious consequences of PHTS relate to the
increased riskof cancers includingbreast, thyroid, endometrial, and
to a lesser extent, renal. Thus far, an increased riskofmalignancyhasonly been documented in CS [Hendriks et al., 2003]. Cancer risk
associated with BRRS is unknown. However, several studies
reported the presentation of thyroid nodules and thyroid cancer
in young children with PHTS [Ngeow et al., 2011; Smith
et al., 2011]. Another report of a malignancy concerned a case of
breast cancer in a BRRS patient (the paternal grandmother of the
proband died at the age 53 years of breast cancer and endometrial
adenocarcinoma) [Longy et al., 1998]. Furthermore, genotype–
phenotype analysis within the BRRS group confirmed that breast
cancer and fibroadenomas have been found in patients with BRRS,
CS, or patients with overlapping features [Marsh et al., 1999].
Therefore, since BRRS and CS are allelic conditions, it may be
warranted to follow patients with BRRS and germ-line PTEN
mutation with the same surveillance protocol. However, no guide-
lines currently exist from this point of view. Recently a prospective
international study proposed new recommendations for manage-
ment of patients with PTENmutation [Tan et al., 2012].We advise
that all patients with PHTS follow a cancer surveillance strategy and
also a specific surveillance for gastrointestinal and vascular com-
plications, as shown in Table IV. In both our patients thyroid
ultrasound examination has never shown any tumor illness. The
fecal occult-blood testing has been negative too. In Patient 2, the
tonsillarmass on the right side became larger and rougher after only
6 months (Fig. 3); hence, tonsillectomy should be performed for
histopathologic examination.
In conclusion, our finding suggest that molecular testing for
PTEN gene mutations in patients with extreme macrocephaly,
developmental delay, and hamartomatous lesions, even in the
absence of other CS/BRRS related clinical features, should be
considered. Clinical management of PHTS patients consists of
an early multidisciplinary surveillance program starting from
diagnosis.
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